Curasight: The company raises capital to accelerate its therapeutic strategy
In their Q3 2023 report, Curasight announced their refocused strategic intention to further accelerate the integration and development of uTRACE and uTREAT – often referred to as the theranostic concept. At the accompanying event with HCA, CEO Ulrich Krasilnikoff and CSO Andreas Kjær explained their ambition to consider a future parallel development of uTRACE and uTREAT rather than the historical development of the two product which has been more sequential in nature. The idea is clearly to bring forward uTREAT since the product candidate for treatment of various cancer types is potentially the most valuable part of Curasight’s pipeline as CSO Andreas Kjær is citing analysts suggesting a value of uTREAT five to ten times bigger than the uTRACE candidate. While clear in their ambition, Curasight yesterday finally shed some lights on the practical execution of the idea as the company proposed a plan to do a Phase I/IIa so-called basket trial of uTRACE and uTREAT combined for five cancer indication adding the two new non-small cell lung and pancreatic cancer to the company’s well-known list of brain cancer, neuroendocrine tumors, and head-and-neck cancer indications.
Basket trial are FDA guided processes that intends to investigate more than one product candidate of various cancer types using the same master protocols. Curasight expects the first patients to be dosed in the beginning of 2025 and first efficacy data available later in 2025 and cites the new trials as the primary reason for the company’s intention to raise capital in a rights issue of DKK 51,2 million taking place from February 23rd to March 7th 2024. An Information Memorandum will be published on February 22nd and on February 27th you can participate in a HCA with CEO Ulrich Krasilnikoff and Andreas Kjær following the release of Curasight’s 2023 report and to learn more of Curasight’s ambition to accelerate its therapeutic strategy and hear details about the right issue.
To participate in the event, you can sign up here: Curasight event
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:35 AM 15-02-2024.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read more on company page
